中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

循环肿瘤DNA在肝细胞癌中的研究现状及展望

侯志远 刘源 杨超然 赵继森 程树杰

引用本文:
Citation:

循环肿瘤DNA在肝细胞癌中的研究现状及展望

DOI: 10.3969/j.issn.1001-5256.2022.11.036
基金项目: 

河北省自然科学基金 18277790D

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:侯志远负责课题设计,资料分析,撰写论文;刘源、杨超然参与收集数据,修改论文;赵继森、程树杰负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    通信作者:

    程树杰,chengshuj@126.com

Current research status and prospect of circulating tumor DNA in hepatocellular carcinoma

Research funding: 

Natural Science Foundation of Hebei Province 18277790D

More Information
  • 摘要: 肝细胞癌(HCC)是世界范围内最常见的恶性肿瘤之一,具有起病隐匿、手术切除率低、易早期转移和复发的特点。近年来,随着新的分子生物学技术的发展,一种液体活检技术——循环肿瘤DNA(ctDNA)检测取得了鼓舞人心的成果。本文综述了ctDNA作为HCC患者液体活检的关键成分的研究现状及未来展望,以期为HCC的临床治疗提供新思路。

     

  • [1] SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
    [2] BEI C, TAN C, ZHU X, et al. Association between polymorphisms in CMTM family genes and hepatocellular carcinoma in Guangxi of China[J]. DNA Cell Biol, 2018, 37(8): 691-696. DOI: 10.1089/dna.2018.4274.
    [3] NG C, di COSTANZO GG, TERRACCIANO LM, et al. Circulating cell-free DNA in hepatocellular carcinoma: current insights and outlook[J]. Front Med (Lausanne), 2018, 5: 78. DOI: 10.3389/fmed.2018.00078.
    [4] LLOVET JM, MONTAL R, SIA D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2018, 15(10): 599-616. DOI: 10.1038/s41571-018-0073-4.
    [5] General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [6] VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15): 1450-1462. DOI: 10.1056/NEJMra1713263.
    [7] ALIX-PANABIÈRES C, PANTEL K. Clinical applications of circulating tumor cells and circulating tumor DNA as Liquid Biopsy[J]. Cancer Discov, 2016, 6(5): 479-491. DOI: 10.1158/2159-8290.CD-15-1483.
    [8] CORCORAN RB, CHABNER BA. Application of cell-free DNA analysis to cancer treatment[J]. N Engl J Med, 2018, 379(18): 1754-1765. DOI: 10.1056/NEJMra1706174.
    [9] MANDEL P, METAIS P. Nuclear acids in human blood plasma[J]. C R Seances Soc Biol Fil, 1948, 142(3-4): 241-243.
    [10] LEON SA, SHAPIRO B, SKLAROFF DM, et al. Free DNA in the serum of cancer patients and the effect of therapy[J]. Cancer Res, 1977, 37(3): 646-650.
    [11] PESSOA LS, HERINGER M, FERRER VP. ctDNA as a cancer biomarker: A broad overview[J]. Crit Rev Oncol Hematol, 2020, 155: 103109. DOI: 10.1016/j.critrevonc.2020.103109.
    [12] KASEB AO, SÁNCHEZ NS, SEN S, et al. Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA[J]. Clin Cancer Res, 2019, 25(20): 6107-6118. DOI: 10.1158/1078-0432.CCR-18-3341.
    [13] WANG M, YE Q, MAO D, et al. Research progress in liver-regenerating microenvironment and DNA methylation in hepatocellular carcinoma: the role of Traditional Chinese Medicine[J]. Med Sci Monit, 2020, 26: e920310. DOI: 10.12659/MSM.920310.
    [14] HEITZER E, HAQUE IS, ROBERTS C, et al. Current and future perspectives of liquid biopsies in genomics-driven oncology[J]. Nat Rev Genet, 2019, 20(2): 71-88. DOI: 10.1038/s41576-018-0071-5.
    [15] von FELDEN J. New systemic agents for hepatocellular carcinoma: an update 2020[J]. Curr Opin Gastroenterol, 2020, 36(3): 177-183. DOI: 10.1097/MOG.0000000000000626.
    [16] ZHU AX, KANG YK, YEN CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2): 282-296. DOI: 10.1016/S1470-2045(18)30937-9.
    [17] von FELDEN J, CRAIG AJ, GARCIA-LEZANA T, et al. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma[J]. Oncogene, 2021, 40(1): 140-151. DOI: 10.1038/s41388-020-01519-1.
    [18] REDDY T, ESMAIL A, CHANG JC, et al. Utility of cell-free DNA Detection in transplant oncology[J]. Cancers (Basel), 2022, 14(3): 743. DOI: 10.3390/cancers14030743.
    [19] NG HI, ZHU X, XUAN L, et al. Analysis of fragment size distribution of cell-free DNA: A potential non-invasive marker to monitor graft damage in living-related liver transplantation for inborn errors of metabolism[J]. Mol Genet Metab, 2019, 127(1): 45-50. DOI: 10.1016/j.ymgme.2019.03.004.
    [20] OKAJIMA W, KOMATSU S, ICHIKAWA D, et al. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids[J]. World J Gastroenterol, 2017, 23(31): 5650-5668. DOI: 10.3748/wjg.v23.i31.5650.
    [21] CHEN VL, XU D, WICHA MS, et al. Utility of liquid biopsy analysis in detection of hepatocellular carcinoma, determination of prognosis, and disease monitoring: A Systematic Review[J]. Clin Gastroenterol Hepatol, 2020, 18(13): 2879-2902. e9. DOI: 10.1016/j.cgh.2020.04.019.
    [22] WENG J, ATYAH M, ZHOU C, et al. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma[J]. Clin Exp Med, 2020, 20(3): 329-337. DOI: 10.1007/s10238-020-00620-9.
    [23] MOHAMED NA, SWIFY EM, AMIN NF, et al. Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C?[J]. Arab J Gastroenterol, 2012, 13(3): 111-115. DOI: 10.1016/j.ajg.2012.06.009.
    [24] ZUCMAN-ROSSI J, VILLANUEVA A, NAULT JC, et al. Genetic landscape and biomarkers of hepatocellular carcinoma[J]. Gastroenterology, 2015, 149(5): 1226-1239. e4. DOI: 10.1053/j.gastro.2015.05.061.
    [25] CAI ZX, CHEN G, ZENG YY, et al. Circulating tumor DNA profiling reveals clonal evolution and real-time disease progression in advanced hepatocellular carcinoma[J]. Int J Cancer, 2017, 141(5): 977-985. DOI: 10.1002/ijc.30798.
    [26] CAI Z, CHEN G, ZENG Y, et al. Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma[J]. Clin Cancer Res, 2019, 25(17): 5284-5294. DOI: 10.1158/1078-0432.CCR-18-3477.
    [27] GARCÍA-FERNÁNDEZ N, MACHER HC, RUBIO A, et al. Detection of p53 mutations in circulating DNA of transplanted hepatocellular carcinoma patients as a biomarker of tumor recurrence[J]. Adv Exp Med Biol, 2016, 924: 25-28. DOI: 10.1007/978-3-319-42044-8_5.
    [28] ZOU YN, YUAN XL. Application value of immunotherapy in hepatocellular carcinoma[J]. J Clin Hepatol, 2021, 37(8): 1758-1760. DOI: 10.3969/j.issn.1001-5256.2021.08.004.

    邹燕梅, 袁响林. 免疫治疗在肝细胞癌中的应用价值[J]. 临床肝胆病杂志, 2021, 37(8): 1758-1760. DOI: 10.3969/j.issn.1001-5256.2021.08.004.
    [29] LI F, QIAO CY, GAO S, et al. Circulating cell-free DNA of methylated insulin-like growth factor-binding protein 7 predicts a poor prognosis in hepatitis B virus-associated hepatocellular carcinoma after hepatectomy[J]. Free Radic Res, 2018, 52(4): 455-464. DOI: 10.1080/10715762.2018.1443448.
    [30] CHAN KC, LAI PB, MOK TS, et al. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma[J]. Clin Chem, 2008, 54(9): 1528-1536. DOI: 10.1373/clinchem.2008.104653.
    [31] WONG IH, LO YM, YEO W, et al. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients[J]. Clin Cancer Res, 2000, 6(9): 3516-3521.
    [32] TANGKIJVANICH P, HOURPAI N, RATTANATANYONG P, et al. Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma[J]. Clin Chim Acta, 2007, 379(1-2): 127-133. DOI: 10.1016/j.cca.2006.12.029.
    [33] HARDING JJ, NANDAKUMAR S, ARMENIA J, et al. Prospective genotyping of hepatocellular carcinoma: Clinical implications of next-generation sequencing for matching patients to targeted and immune therapies[J]. Clin Cancer Res, 2019, 25(7): 2116-2126. DOI: 10.1158/1078-0432.CCR-18-2293.
    [34] ZHANG ZC, SUN LC, SUN QY, et al. Global research hotspots and trends in the field of immunotherapy for liver cancer in 2011-2020 based on CiteSpace analysis[J]. J Clin Hepatol, 2021, 37(12): 2843-2848. DOI: 10.3969/j.issn.1001-5256.2021.12.022.

    张稚淳, 孙力超, 孙秋月, 等. 基于CiteSpace分析2011年-2020年全球肝癌免疫治疗研究领域的热点及趋势[J]. 临床肝胆病杂志, 2021, 37(12): 2843-2848. DOI: 10.3969/j.issn.1001-5256.2021.12.022.
    [35] ZHANG Y, LIU Z, JI K, et al. Clinical application value of circulating cell-free DNA in hepatocellular carcinoma[J]. Front Mol Biosci, 2021, 8: 736330. DOI: 10.3389/fmolb.2021.736330.
    [36] CHAN SL, WONG AM, LEE K, et al. Personalized therapy for hepatocellular carcinoma: Where are we now?[J]. Cancer Treat Rev, 2016, 45: 77-86. DOI: 10.1016/j.ctrv.2016.02.008.
    [37] SCHWAEDERLÉ M, LAZAR V, VALIDIRE P, et al. VEGF-A expression correlates with TP53 mutations in non-small cell lung cancer: Implications for antiangiogenesis therapy[J]. Cancer Res, 2015, 75(7): 1187-1190. DOI: 10.1158/0008-5472.CAN-14-2305.
    [38] CHANG Y, TOLANI B, NIE X, et al. Review of the clinical applications and technological advances of circulating tumor DNA in cancer monitoring[J]. Ther Clin Risk Manag, 2017, 13: 1363-1374. DOI: 10.2147/TCRM.S141991.
    [39] IKEDA S, TSIGELNY IF, SKJEVIK ÅA, et al. Next-generation sequencing of circulating tumor DNA reveals frequent alterations in advanced hepatocellular carcinoma[J]. Oncologist, 2018, 23(5): 586-593. DOI: 10.1634/theoncologist.2017-0479.
    [40] LIM HY, MERLE P, WEISS KH, et al. Phase Ⅱ studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular carcinoma[J]. Clin Cancer Res, 2018, 24(19): 4650-4661. DOI: 10.1158/1078-0432.CCR-17-3588.
    [41] GALLE E, THIENPONT B, CAPPUYNS S, et al. DNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer[J]. Clin Epigenetics, 2020, 12(1): 27. DOI: 10.1186/s13148-020-0821-z.
    [42] JIN Y, CHEN DL, WANG F, et al. The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors[J]. Mol Cancer, 2020, 19(1): 154. DOI: 10.1186/s12943-020-01274-7.
    [43] LIU YY. New progress of hepatocellular carcinoma treatment[J]. Chin J Dig Surg, 2022, 21(1): 15-18. DOI: 10.3760/cma.j.cn115610-20220107-00020.

    刘允怡. 肝细胞癌治疗的新发展[J]. 中华消化外科杂志, 2022, 21(1): 15-18. DOI: 10.3760/cma.j.cn115610-20220107-00020.
    [44] BRUIX J, SHERMAN M, American association for the study of liver diseases. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3): 1020-1022. DOI: 10.1002/hep.24199.
    [45] VOSO MT, OTTONE T, LAVORGNA S, et al. MRD in AML: The role of new techniques[J]. Front Oncol, 2019, 9: 655. DOI: 10.3389/fonc.2019.00655.
    [46] SCHUURHUIS GJ, HEUSER M, FREEMAN S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party[J]. Blood, 2018, 131(12): 1275-1291. DOI: 10.1182/blood-2017-09-801498.
    [47] WANG J, HUANG A, WANG YP, et al. Circulating tumor DNA correlates with microvascular invasion and predicts tumor recurrence of hepatocellular carcinoma[J]. Ann Transl Med, 2020, 8(5): 237. DOI: 10.21037/atm.2019.12.154.
    [48] LEE TH, MONTALVO L, CHREBTOW V, et al. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma[J]. Transfusion, 2001, 41(2): 276-282. DOI: 10.1046/j.1537-2995.2001.41020276.x.
    [49] HU Y, ULRICH BC, SUPPLEE J, et al. False-positive plasma genotyping due to clonal hematopoiesis[J]. Clin Cancer Res, 2018, 24(18): 4437-4443. DOI: 10.1158/1078-0432.CCR-18-0143.
    [50] YANG YC, WANG D, JIN L, et al. Circulating tumor DNA detectable in early-and late-stage colorectal cancer patients[J]. Biosci Rep, 2018, 38(4): BSR20180322. DOI: 10.1042/BSR20180322.
    [51] DHAYAT SA, YANG Z. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas[J]. J Cancer Res Clin Oncol, 2020, 146(7): 1625-1645. DOI: 10.1007/s00432-020-03219-5.
  • 加载中
计量
  • 文章访问数:  77
  • HTML全文浏览量:  41
  • PDF下载量:  25
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-04-01
  • 录用日期:  2022-06-30
  • 出版日期:  2022-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回